« BackCancer Letters
Article in Press

Targeting apoptosis pathways in cancer by Chinese medicine

  • Min Li-Weber

      Affiliations

    • Corresponding Author InformationAddress: Tumor Immunology Program D030, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Tel.: +49 6221 423748; fax: +49 6221 411715.

Tumor Immunology Program (D030), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

Received 19 May 2010; received in revised form 11 July 2010; accepted 13 July 2010. published online 04 August 2010.
Corrected Proof

Abstract 

The traditional Chinese medicine (TCM) uses a combination of different natural products based on practical experiences. To better understand the therapeutic functions of TCM, large efforts have been made to identify the principle constituents of TCM and to unravel the molecular mechanisms behind the efficacy observed. This review aims to summarize research results obtained from the most intensively studied TCM phytochemical compounds namely the alkaloids Berberine, Evodiamine; anthraquinones Emodin, Aloe-emodin, Rhein; the terpenoids Artemisinin, Celastrol, Triptolide; the flavones Apigenin, Chrysin, Wogonin, Baicalein; and the cyclopenta[b]benzofuran derivatives Rocaglamide. Most of them have been originally identified as anti-inflammatory and anti-viral reagents and are now known to also possess anti-tumor activities by targeting the apoptosis pathways in cancer. This review also intends to give an overview of the mechanisms of action identified so far. These breakthrough findings may have important implications for targeted-cancer therapy and for modernization of TCM.

Keywords: Cancer, Apoptosis, ROS, DNA damage, NF-κB, MAPK, Drug

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(10)00363-0

doi:10.1016/j.canlet.2010.07.015

« BackCancer Letters